Stepwise Screening for Silent Atrial Fibrillation After Stroke
- Conditions
- Ischemic Cerebrovascular Accident
- Registration Number
- NCT03570060
- Lead Sponsor
- Centre Hospitalier Universitaire Dijon
- Brief Summary
The main hypothesis of this work is that an approach combining clinical parameters and biomarker assays could improve the understanding and prediction of the occurrence of silent atrial fibrillation (AF) in the acute phase after stroke. In this prospective work, the investigators will rely on the Dijon Stroke Registry, which collects extensive clinical data for each patient hospitalized for a stroke. As part of this registry, patients are seen 6 months after stroke to assess their clinical status. This clinical follow-up will allow us to judge the evolution of the AF diagnosed during the acute episode at a distance.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 264
- Patient who had an ischemic stroke defined according to WHO criteria and hospitalized in the Stroke Unit at the Dijon University Hospital.
- Patient 18 years of age and older
- Patient who has given oral consent
- Person not affiliated to a national health insurance scheme
- Protected adult
- Pregnant or breastfeeding woman
- Patient refusing to participate in the study
- Transfer planned after the stay in the Stroke Unit to a department outside the Dijon University Hospital, not allowing for the long term screening with an external ECG monitor
- History of atrial fibrillation or atrial flutter
- Patient wearing a pacemaker or defibrillator with an atrial lead
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Diagnosis of atrial fibrillation during continuous monitoring in a Stroke unit within six months of stroke. 6 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (1)
CHU Dijon Bourgogne
🇫🇷Dijon, France
CHU Dijon Bourgogne🇫🇷Dijon, France